Clear Search sequence regions

  • agents patients (1)
  • humans (1)
  • patients (5)
  • stroke (2)
  • Sizes of these terms reflect their relevance to your search.

    There is uncertainty regarding the optimal therapy for preventing thromboembolic stroke in patients with atrial fibrillation and CHA(2)DS(2)-VASc score 1. In fact, no extensive data on this topic are available, and the latest guidelines provide different recommendations. In this article, we examine current results on the use of various antithrombotic agents, including the newer oral anticoagulant agents, in those patients. Several factors must be considered and weighted in this setting and may influence the choice of the antithrombotic approach: the expected incidence of both thromboembolic stroke and bleeding complications as well as their impact in terms of morbidity and mortality, the patient's bleeding risk profile, an accurate, further stratification of the thromboembolic risk beyond the CHA(2)DS(2)-VASc score, and socioeconomic issues. Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.


    Giuseppe Patti, Ilaria Cavallari. Patients with atrial fibrillation and CHA2DS2-VASc score 1: "To anticoagulate or not to anticoagulate? That is the question!". Heart rhythm : the official journal of the Heart Rhythm Society. 2015 Dec;12(12):2515-20

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 26188249

    View Full Text